/CRVO
CRVO Stock - CervoMed Inc.
Healthcare|BiotechnologyNASDAQ
$7.60-3.80%
$0.30 (-3.80%) • Dec 19
73
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.30
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+196.1%upside
Target: $22.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CRVO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.52 – $7.68
TARGET (TP)$22.50
STOP LOSS$6.99
RISK/REWARD1:24.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-6.48
52W High$16.94
52W Low$1.92
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-103,168 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-18,227,131 | $-7,812,895 | $-3,475,534 | $-24,677,107 | $-15,975,000 |
| Net Income | $-16,290,695 | $-2,171,873 | $-5,803,047 | $-24,095,727 | $-14,185,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.02 | $-0.82 | $-11.20 | $-18.51 | $-22.50 |
Company Overview
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
63%
Hold / Neutral
3
38%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
5 Bullish3 Neutral/Bearish
Price Targets
$40
Average Target
↑ 428.5% Upside
Now
$14
Low
$40
Average
$55
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 18th 2025 | Cantor Fitzgerald | Initiation | Overweight | - |
| March 13th 2025 | Chardan Capital Markets | Upgrade | Buy | $14 |
| December 17th 2024 | H.C. Wainwright | Downgrade | Neutral | - |
| December 11th 2024 | Chardan Capital Markets | Downgrade | Neutral | - |
| December 11th 2024 | Morgan Stanley | Downgrade | Underweight | - |
| December 10th 2024 | D. Boral Capital | Downgrade | Hold | - |
| December 6th 2024 | ROTH MKM | Initiation | Buy | $45 |
| December 5th 2024 | H.C. Wainwright | Initiation | Buy | $42 |
| September 18th 2024 | Chardan Capital Markets | Initiation | Buy | $55 |
| July 26th 2024 | Morgan Stanley | Initiation | Overweight | $35 |
| February 15th 2024 | Canaccord Genuity | Initiation | Buy | $50 |
Earnings History & Surprises
CRVOBeat Rate
43%
Last 14 quarters
Avg Surprise
-0.5%
EPS vs Estimate
Beats / Misses
6/8
Last 12 quarters
Latest EPS
$-0.84
Q4 2025
EPS Surprise History
Q1 24
-31.0%
$-0.38vs$-0.29
Q2 24
+10.9%
$-0.41vs$-0.46
Q3 24
-12.5%
$-0.27vs$-0.24
Q4 24
-34.1%
$-0.55vs$-0.41
Q1 25
-19.4%
$-0.80vs$-0.67
Q2 25
+6.7%
$-0.56vs$-0.60
Q3 25
-22.8%
$-0.70vs$-0.57
Q4 25
-23.5%
$-0.84vs$-0.68
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 16, 2026 | $-0.79 | — | — | — |
Q4 2025 | Nov 7, 2025 | $-0.68 | $-0.84 | -23.5% | ✗ MISS |
Q3 2025 | Aug 8, 2025 | $-0.57 | $-0.70 | -22.8% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-0.60 | $-0.56 | +6.7% | ✓ BEAT |
Q1 2025 | Mar 17, 2025 | $-0.67 | $-0.80 | -19.4% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.41 | $-0.55 | -34.1% | ✗ MISS |
Q3 2024 | Aug 9, 2024 | $-0.24 | $-0.27 | -12.5% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.46 | $-0.41 | +10.9% | ✓ BEAT |
Q1 2024 | Mar 25, 2024 | $-0.29 | $-0.38 | -31.0% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.95 | $-0.70 | +26.3% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-2.90 | $-1.04 | +64.1% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-2.87 | $-3.01 | -5.0% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | $-3.30 | $-3.00 | +9.2% | ✓ BEAT |
Q3 2022 | Sep 29, 2022 | $-3.09 | $-2.06 | +33.4% | ✓ BEAT |
Q2 2022 | Jun 29, 2022 | — | $-3.08 | — | — |
Q1 2022 | Mar 30, 2022 | $-3.06 | $-3.33 | -8.9% | ✗ MISS |
Q4 2021 | Dec 30, 2021 | — | $-2.56 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-8.98 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-2.78 | — | — |
Latest News
Cantor Fitzgerald Initiates Coverage On CervoMed with Overweight Rating
📈 PositiveBenzinga•Dec 18, 2025, 01:02 PM
HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target
📈 PositiveBenzinga•Dec 18, 2025, 12:07 PM
D. Boral Capital Maintains Buy on CervoMed, Maintains $31 Price Target
📈 PositiveBenzinga•Dec 5, 2025, 12:15 PM
CervoMed's Neflamapimod Reports Phase 2b Results In DLB Patients, Showed Significant Improvements On Primary And Key Secondary Outcomes Measure; Phase 3 Trial Set for H2 2026
📈 PositiveBenzinga•Dec 4, 2025, 10:02 PM
D. Boral Capital Maintains Buy on CervoMed, Maintains $31 Price Target
📈 PositiveBenzinga•Dec 2, 2025, 01:48 PM
CervoMed Shared New Data From Phase 2B RewinD-LB Trial Demonstrating Neflamapimod Treatment Led To A Significant Reduction In Neurodegeneration Biomarker Plasma
📈 PositiveBenzinga•Dec 2, 2025, 12:08 PM
CervoMed's Neflamapimod, Oral, Small Molecule, Targeting Critical Disease Processes Underlying Degenerative Disorders Of Brain, To Be Featured In Two Presentations At CTAD 2025
📈 PositiveBenzinga•Nov 24, 2025, 12:10 PM
D. Boral Capital Maintains Buy on CervoMed, Maintains $31 Price Target
📈 PositiveBenzinga•Nov 11, 2025, 12:23 PM
CervoMed Q3 EPS $(0.84) Misses $(0.49) Estimate, Sales $322.569K Miss $1.300M Estimate
📉 NegativeBenzinga•Nov 10, 2025, 12:21 PM
HC Wainwright & Co. Upgrades CervoMed to Buy, Raises Price Target to $25
📈 PositiveBenzinga•Nov 5, 2025, 11:35 AM
D. Boral Capital Maintains Buy on CervoMed, Maintains $31 Price Target
📈 PositiveBenzinga•Nov 4, 2025, 01:41 PM
CervoMed Announces FDA Alignment On Key Aspects Of Phase 3 Neflamapimod Trial In Dementia With Lewy Bodies
📈 PositiveBenzinga•Nov 4, 2025, 12:12 PM
CervoMed Shares Additional Data From Phase 2b RewinD-LB Trial, Further Demonstrating Neflamapimod's Potential For Dementia With Lewy Bodies
📈 PositiveBenzinga•Oct 8, 2025, 11:03 AM
CervoMed Highlights Dementia Drug Results at Major Neurology Conference
📈 PositiveBenzinga•Sep 17, 2025, 11:42 AM
HC Wainwright & Co. Reiterates Neutral on CervoMed, Announces $11 Price Target
➖ NeutralBenzinga•Sep 8, 2025, 10:55 AM
D. Boral Capital Maintains Buy on CervoMed, Raises Price Target to $31
📈 PositiveBenzinga•Aug 18, 2025, 11:45 AM
Frequently Asked Questions about CRVO
What is CRVO's current stock price?
CervoMed Inc. (CRVO) is currently trading at $7.60 per share. The stock has moved -3.80% today.
What is the analyst price target for CRVO?
The average analyst price target for CRVO is $22.50, based on 1 analyst.
What sector is CervoMed Inc. in?
CervoMed Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CRVO's market cap?
CervoMed Inc. has a market capitalization of $0.07 billion, making it a small-cap company.
Does CRVO pay dividends?
No, CervoMed Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACET
Adicet Bio, Inc.
$0.49
Mkt Cap: $0.0B
ADAG
Adagene Inc.
$1.82
Mkt Cap: $0.1B
FBIO
Fortress Biotech, Inc.
$3.54
Mkt Cap: $0.1B
GANX
Gain Therapeutics, Inc.
$2.88
Mkt Cap: $0.1B
LITS
Lite Strategy, Inc.
$1.43
Mkt Cap: $0.1B
NRXP
NRx Pharmaceuticals, Inc.
$2.37
Mkt Cap: $0.0B
NTRB
Nutriband Inc.
$4.49
Mkt Cap: $0.1B
OSTX
OS Therapies Incorporated
$1.54
Mkt Cap: $0.1B
VTVT
vTv Therapeutics Inc.
$36.01
Mkt Cap: $0.1B
XBIT
XBiotech Inc.
$2.50
Mkt Cap: $0.1B
Explore stocks similar to CRVO for comparison